WO2011109130A1 - Fils d'acide hyaluronique et leurs méthodes d'utilisation - Google Patents

Fils d'acide hyaluronique et leurs méthodes d'utilisation Download PDF

Info

Publication number
WO2011109130A1
WO2011109130A1 PCT/US2011/022640 US2011022640W WO2011109130A1 WO 2011109130 A1 WO2011109130 A1 WO 2011109130A1 US 2011022640 W US2011022640 W US 2011022640W WO 2011109130 A1 WO2011109130 A1 WO 2011109130A1
Authority
WO
WIPO (PCT)
Prior art keywords
thread
threads
hyaluronic acid
mda
needle
Prior art date
Application number
PCT/US2011/022640
Other languages
English (en)
Inventor
Geoffrey C. Gurtner
Jayakumar Rajadas
Kenneth Horne
Hiram Chee
Original Assignee
Tautona Group Lp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tautona Group Lp filed Critical Tautona Group Lp
Publication of WO2011109130A1 publication Critical patent/WO2011109130A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/04—Surgical instruments, devices or methods, e.g. tourniquets for suturing wounds; Holders or packages for needles or suture materials
    • A61B17/06—Needles ; Sutures; Needle-suture combinations; Holders or packages for needles or suture materials
    • A61B17/06166—Sutures
    • D—TEXTILES; PAPER
    • D01—NATURAL OR MAN-MADE THREADS OR FIBRES; SPINNING
    • D01D—MECHANICAL METHODS OR APPARATUS IN THE MANUFACTURE OF ARTIFICIAL FILAMENTS, THREADS, FIBRES, BRISTLES OR RIBBONS
    • D01D5/00—Formation of filaments, threads, or the like
    • D—TEXTILES; PAPER
    • D01—NATURAL OR MAN-MADE THREADS OR FIBRES; SPINNING
    • D01F—CHEMICAL FEATURES IN THE MANUFACTURE OF ARTIFICIAL FILAMENTS, THREADS, FIBRES, BRISTLES OR RIBBONS; APPARATUS SPECIALLY ADAPTED FOR THE MANUFACTURE OF CARBON FILAMENTS
    • D01F9/00—Artificial filaments or the like of other substances; Manufacture thereof; Apparatus specially adapted for the manufacture of carbon filaments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B2017/00743—Type of operation; Specification of treatment sites
    • A61B2017/00747—Dermatology
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B2017/00831—Material properties
    • A61B2017/00893—Material properties pharmaceutically effective

Definitions

  • This invention relates generally to threads of hyaluronic acid, methods of making such threads and uses thereof, for example, in aesthetic applications (e.g., facial contouring, dermal fillers), surgery (e.g., sutures), drug delivery, negative pressure wound therapy, moist wound dressing, and the like.
  • aesthetic applications e.g., facial contouring, dermal fillers
  • surgery e.g., sutures
  • drug delivery e.g., negative pressure wound therapy, moist wound dressing, and the like.
  • Hyaluronic acid is a linear polysaccharide (i.e., non-sulfated glycosaminoglycan) consisting of a repeated disaccharide unit of alternately bonded ⁇ -D-N-acetylglucoamine and ⁇ -D- glucuronic acid which can be depicted by the formula:
  • Hyaluronic acid is sometimes referred to by the nomenclature (-4GlcUA i-3GlcNAc i-) n ) and is a chief component of the extracellular matrix found, for example, in connective, epithelial and neural tissue. Natural hyaluronic acid is highly biocompatible because of its lack of species and organ specificity and is often used as a biomaterial in tissue engineering and as a common ingredient in dermal fillers.
  • Natural hyaluronic acid has poor in vivo stability due to rapid enzymatic degradation and hydrolysis and, accordingly, various chemically modified forms of hyaluronic acid (e.g., cross- linked forms, ionically modified forms, esterified forms, etc.) have been synthesized to address this problem.
  • hyaluronic acid or cross-linked versions thereof are used in various gel forms, for example as dermal fillers, adhesion barriers, and the like.
  • Hyaluronic acid like collagen, is known to form triple-helices through hydrogen bonding. It has now been surprisingly found that a secondary organization, referred to herein as “interlocked,” can be made to occur with hyaluronic acid. As contemplated herein, these secondary structures of hyaluronic acid are "interlocked" when a matrix of hyaluronic acid is formed upon dehydration under non-denaturing conditions. Such a matrix can comprise one or multiple hyaluronic acid polymers wherein the polymers are substantially parallel to one another, and/or the helices are substantially parallel to each other and/or the polymers/helices are intertwined among each other. [0008] The exact nature of the interlocking is not critical.
  • the criticality of the interlocked structures when in the form of a thread, is manifested in one or more of the following: improved tensile strength, reduced biodegradation, improved ability to promote fibrogenesis, and the like.
  • An improved ability to promote fibrogenesis and/or tissue repair in vivo is provided by forming a scaffold-like structure in the body for collagen deposition. This tissue repair could prolong the "filler” or "rejuvenation” effects of the thread when used to treat or fill a wrinkle or provide facial contouring in vivo far beyond the half-life of the hyaluronic acid-based thread.
  • the present invention is directed to a thread comprising hyaluronic acid wherein at least a portion of the hyaluronic acid is interlocked. It is contemplated that the interlocking of the hyaluronic acid can be confirmed by its ability to reflect polarized light, scanning electron microscopy (SEM), transmission electron microscopy (TEM), atomic force microscopy (AFM) and/or x-ray diffraction (XRD).
  • the thread is substantially cylindrical, substantially D-shaped, or substantially ribbon shaped.
  • Hyaluronic acid forms a gel under aqueous conditions. This gel form can then be converted by the methods described herein to provide the novel threads of this invention.
  • an aqueous gel composition comprising hyaluronic acid is dried under non-denaturing conditions, and preferably ambient conditions, to provide a dried thread.
  • a method of treating a wrinkle in a subject in need thereof is provided.
  • the thread is inserted into the dermis of a patient adjacent to or under the wrinkle.
  • the thread is then applied under the wrinkle thereby treating the wrinkle.
  • the thread upon exposure to body fluids or by manually hydrating, the thread expands upon hydration and such expansion is typically sufficient to fill-in the wrinkle. It is advantageous to have a thread expand upon hydration because the invasiveness of the insertion profile is minimized, however, threads designed to not expand can also be used to treat the wrinkle.
  • the invention is directed to providing facial contouring in a subject in need thereof.
  • the thread is inserted into the dermis at or adjacent to the desired treatment location, e.g., the lips, the nasolabial fold, the tear trough, etc.
  • the thread is then applied thereby providing facial contouring.
  • a thread is applied to various planes of the dermal tissue.
  • several threads can be placed generally parallel to each other and additional threads places in a generally perpendicular direction with respect to the first set of parallel threads thereby forming a mesh structure whose aggregate effect is to contour a larger defect or more widespread defect such as the tear trough or the infraorbital region of the eye.
  • kits of parts comprising the thread.
  • the kit further comprises a means for delivering the thread.
  • the means for delivery can either be a syringe or a needle.
  • threads of hyaluronic acid as dermal fillers, facial contouring, adhesion barriers, wound dressings including negative pressure wound dressings, sutures, and the like is provided. Further provided are methods of using threads of hyaluronic acid for example, in surgery, ophthalmology, wound closure, drug delivery, and the like. These embodiments, as well as others, are discussed in more detail below.
  • Fig. 1 shows images of various HA compositions taken with a bench top polarization setup where the polarization angle was aligned.
  • FIG. 2 shows scanning electron microscopy (SEM) images of a HA gel (Fig. 2A) compared to a HA thread (Figs. 2B, 2C, and 2D).
  • Fig. 4A illustrates a close-up view of a thread inserted into the inner-diameter of a needle; and
  • Fig. 4B illustrates a close-up view of the distal end of a solid needle with the thread overlapping the needle.
  • Fig. 5 shows treatment of a wrinkle.
  • Fig. 5A illustrates a fine, facial wrinkle in the periorbital region of a human;
  • Fig. 5B illustrates a needle and thread being inserted into the dermis of the wrinkle at the medial margin;
  • Fig. 5C illustrates the needle being adjusted to traverse beneath the wrinkle;
  • Fig. 5A illustrates a fine, facial wrinkle in the periorbital region of a human
  • Fig. 5B illustrates a needle and thread being inserted into the dermis of the wrinkle at the medial margin
  • Fig. 5C illustrates the needle being adjusted to traverse
  • FIG. 5D illustrates the needle exiting at the lateral margin of the wrinkle
  • Fig. 5E illustrates the needle having pulled the thread into the location it previously occupied beneath the wrinkle
  • Fig. 5F illustrates the thread implanted beneath the wrinkle, with excess thread having been cut off.
  • FIG. 6 shows treatment of baldness.
  • Fig. 6A illustrates a top-down view of a male with typical male-pattern baldness
  • Fig. 6B illustrates where hair re-growth is desired, taking hair-lines into consideration
  • Fig. 6C illustrates a curved needle with attached thread being inserted into one imaginary line where hair re-growth is desired
  • Fig. 6D illustrates the needle traversing the imaginary line, and exiting the skin
  • Fig. 6E illustrates the needle pulled through distally, pulling along the thread into the desired location
  • Fig. 6F illustrates scissors being used to cut excess thread.
  • Fig. 7 shows treatment of a wrinkle.
  • Fig. 6A illustrates a top-down view of a male with typical male-pattern baldness
  • Fig. 6B illustrates where hair re-growth is desired, taking hair-lines into consideration
  • Fig. 6C illustrates a curved needle with attached thread being inserted into one imaginary line where hair re-growth is
  • FIG. 7A illustrates a cross-sectional view of a fold or a wrinkle
  • Fig. 7B illustrates a thread implanted beneath a wrinkle that is not yet hydrated
  • Fig. 7C illustrates a thread implanted beneath a wrinkle that is fully hydrated and has flattened the surface appearance of the wrinkle.
  • FIG. 8 shows treatment of a tumor.
  • Fig. 8A illustrates a human pancreas with a tumor;
  • Fig. 8B illustrates a curved needle with a thread attached thereto;
  • Fig. 8C illustrates a curved needle traversing the tumor within the pancreas; and
  • Fig. 8D illustrates the end-result of repeated implantations of thread.
  • Fig. 9 shows a nipple reconstruction.
  • Fig. 9A illustrates multiple layers of concentric coils of thread, shaped to represent a human nipple;
  • Fig. 9B illustrates the implant of Fig. 9A in cross-section;
  • Fig. 9C illustrates how an implant of coiled thread would be used for nipple reconstruction.
  • Fig. 10 illustrates how a needle and thread could be used to place a thread in a specific, linear location to promote nerve or vessel regrowth in a specific line.
  • Fig. 1 1 shows photographs of the cross sectional shape of various threads of the invention under a microscope.
  • Fig. 11 A shows a substantially cylindrical thread
  • Fig. 1 IB shows a substantially D-shaped thread
  • Fig. 11 C shows a substantially ribbon-shaped thread. The thread was taped onto an aluminum surface and cut to reveal the cross-sectional shape.
  • Fig. 12 shows transmission electron microscopy (TEM) images of the gel (Figs. 12A and 12B) and a thread of the invention (Figs. 12C and 12D). Figs. 12A - 12D are discussed in Example 10.
  • TEM transmission electron microscopy
  • Fig. 13A and 13B shows the front view a patient who has received lip augmentation with threads of the invention.
  • Fig. 13A is before and Fig. 13B is after.
  • four threads were used in the patient's upper lip.
  • On each side of the lip one thread was placed at the white roll and one at the wet-dry junction.
  • For the lower lip one thread was placed in the white roll on both the left and right side of the lip. Also, there was one thread implanted in the middle at the wet-dry junction.
  • Fig. 14A and 14B shows the same patient from the side view where Fig. 14A is before and Fig. 14B is after.
  • Fig. 15A and 15B is the same patient from the opposite side where Fig. 15A is before and Fig. 15B is after.
  • FIG. 16A and 16B shows the front view of a patient who has had threads of the invention implanted into the tear trough.
  • Fig. 16A is before and Fig. 16B is after.
  • the patient in this photo had 3 threads implanted in the tear trough.
  • the threads were placed substantially parallel at mid- depth (which is considered the deep dermis).
  • the threads were placed about 1 millimeter apart in a substantially parallel fashion to the axis of the trough.
  • FIG. 17A and 17B shows the before and after of a patient who has had threads of the invention implanted into the nasolabial folds.
  • 4 threads were used on the right side (2 threads were implanted in approximately the subcutaneous space, 1 thread in the deep dermis, and 1 thread in the superficial dermis).
  • On the left side four threads were used (1 thread was implanted in approximately the subcutaneous space, 2 threads in the deep dermis, and 1 thread in the superficial dermis).
  • FIG. 18A and 18B shows the before and after of a patient who has had threads of the invention implanted into the forehead.
  • Fig. 19A shows placement of threads in a relatively parallel orientation for facial contouring in the tear trough (Thread 1 , 2, 3, 4, 5, and 6). This figure also shows placement of the thread for facial contouring of the nasolabial fold (Thread 7 and 8).
  • Fig. 19B shows an alternative placement of the threads for facial contouring in the tear trough (Thread 1, 2, 3, 4, 5, 6, 7, and 8).
  • Figs. 20A and 20B show a schematic of the contemplated microanatomy of a thread implanted into a patient both in a cross-section of the skin and a three-dimensional cross-section.
  • This invention is directed to threads of hyaluronic acid, methods for their preparation and uses thereof and to specific shapes formed there from. However, prior to describing this invention in greater detail, the following terms will first be defined.
  • compositions and methods are intended to mean that the compositions and methods include the recited elements, but not excluding others.
  • Consisting essentially of when used to define compositions and methods shall mean excluding other elements of any essential significance to the combination for the stated purpose. Thus, a composition consisting essentially of the elements as defined herein would not exclude other materials or steps that do not materially affect the basic and novel characteristic(s) of the claimed invention.
  • Consisting of shall mean excluding more than trace elements of other ingredients and substantial method steps. Embodiments defined by each of these transition terms are within the scope of this invention.
  • the invention is directed to a thread of hyaluronic acid wherein at least a portion is interlocked.
  • the term “thread” refers to a long, thin, flexible form of a material.
  • the thread of the invention can have a variety of shapes in the cross-section which are discussed below.
  • the term “hyaluronic acid” or “HA” refers to the polymer having the formula:
  • n is the number of repeating units.
  • All sources of hyaluronic acid are useful in this invention, including bacterial and avian sources.
  • Hyaluronic acids useful in this invention have a molecular weight of from about 0.5 MDa (mega Dalton) to about 3.0 MDa. In some
  • the molecular weight is from about 0.6 MDa to about 2.6 MDa and in yet another embodiment, the molecular weight is from about 1.2 MDa to about 1.8 MDa, or from about 1.4 MDa to about 1.6 MDa.
  • the term "interlocked" refers to a matrix of hyaluronic acid that is formed upon dehydration under non-denaturing conditions.
  • a matrix can comprise one or multiple hyaluronic acid polymers wherein the polymers are substantially parallel to one another, or the helices are substantially parallel to each other and/or the polymers/helices are intertwined among each other along an axis.
  • at least about 20% of the helices are substantially parallel to each other.
  • at least about 50%> of the helices are substantially parallel to each other.
  • the interlocking can occur prior to, during, or after the hyaluronic acid's organization into triple helices. In one embodiment, at least about 10%> is interlocked. In another embodiment, at least about 30%> is interlocked.
  • non-denaturing conditions refers to conditions which preserve interlocking.
  • non-denaturing conditions include ambient conditions.
  • non-denaturing conditions include the use of a desiccant.
  • ambient conditions is intended to refer to the typical environmental conditions and preferably, a pressure of about 1 atmosphere and/or temperature of 5 °C to about 40 °C, and preferably 20 °C to 30 °C.
  • the ambient conditions comprise a relative humidity of from about 20% to about 80%>.
  • percent hydration is intended to refer to the total percent of water by weight. In one embodiment, the percent hydration of the thread is about 30%> or less, or alternatively, about 15%) or less, or alternatively, about 10%> or less. This can typically be measured by Karl Fisher titration.
  • the term "ultimate tensile strength” is intended to refer to the tensile strength of the thread which has been normalized with respect to cross-sectional area.
  • the term “tensile strength” is intended to refer to the maximum stress a thread can withstand without failing when subjected to tension. In one embodiment, it is contemplated that the ultimate tensile strength is sufficient to pull the thread through the dermis and manipulate it once in the dermis such that the integrity of the thread is not substantially compromised by, for example, breaking or segmenting.
  • threads of the invention preferably have an ultimate tensile strength of about 3 kpsi ("kilopounds per square inch") or greater, or 5 kpsi or greater, or 10 kpsi or greater, or 15 kpsi or greater or 20 kpsi or greater or 50 kpsi or greater or 75 kpsi or greater.
  • the threads of the invention can be made into a variety of shapes. The term
  • substantially cylindrical refers to a thread wherein the cross-section of the thread is round.
  • the term “substantially” as used to refer to shapes of the threads means that at least 50%> of the thread has the shaped described.
  • the term substantially is also used to encompass threads which have a variety shapes along the length of the thread. For example, a thread could be substantially cylindrical but the ends of the thread may be tapered.
  • the substantially cylindrical threads can be provided when the contact angle of the gel composition and the substrate on which it is extruded have an equilibrium contact angle of greater than about 90 degrees.
  • substantially D-shaped refers to a thread wherein the cross-section is D- shaped or substantially semi-circular.
  • the substantially D-shaped threads have one flat side and one substantially round side.
  • the substantially D-shaped threads can be provided when the contact angle of the gel composition and the substrate on which it is extruded have an equilibrium contact angle of about 90 degrees.
  • substantially ribbon-shaped refers to a thread wherein the thickness of the thread is less than about 50%> of the width of the thread.
  • the cross-section is substantially rectangular.
  • the ribbon-shaped threads can be provided when the contact angle of the gel composition and the substrate on which it is extruded have an equilibrium contact angle of less than about 90 degrees.
  • the ribbon-shaped threads can be formed by cutting a wetted gel to achieve the desired cross-sectional shape.
  • “Ribbon-shaped” may also include shapes that are substantially ellipsoidal.
  • substantially ellipsoidal refers to a thread wherein the cross-section is substantially oblong or elliptical.
  • the term "therapeutic agent” can include one or more therapeutic agents.
  • the therapeutic agent is an anesthetic, including but not limited to, lidocaine, xylocaine, novocaine, benzocaine, prilocaine, ripivacaine, propofol or combinations thereof.
  • the therapeutic agent includes, but is not limited to, epinephrine, adrenaline, ephedrine, aminophylline, theophylline or combinations thereof.
  • the therapeutic agent is botulism toxin.
  • the therapeutic agent is laminin-51 1.
  • the therapeutic agent is glucosamine, which can be used, for example, in the treatment of regenerative joint disease.
  • the therapeutic agent is an antioxidant, including but not limited to, vitamin E or all-trans retinoic acid such as retinol.
  • the therapeutic agent includes stem cells.
  • the therapeutic agent is insulin, a growth factor such as, for example, NGF (nerve growth factor),BDNF (brain-derived neurotrophic factor), PDGF (platelet- derived growth factor) or Purmorphamine Deferoxamine NGF (nerve growth factor),
  • dexamethasone ascorbic acid, 5-azacytidine, 4,6-disubstituted pyrrolopyrimidine, cardiogenols, cDNA, DNA, RNAi, BMP-4 (bone morphogenetic protein-4), BMP -2 (bone morphogenetic protein-2), an antibiotic agent such as, for example, ⁇ lactams, quinolones including
  • an anti-fibrotic agent including but not limited to, hepatocyte growth factor or Pirfenidone, an anti-scarring agent, such as, for example, anti- TGF-b2 monoclonal antibody (rhAnti-TGF-b2 mAb), a peptide such as, for example, GHK copper binding peptide, a tissue regeneration agent, a steroid, fibronectin, a cytokine, an analgesic such as, for example, Tapentadol HC1, opiates, (e.g., morphine, codone, oxycodone, etc.) an antiseptic, alpha- beta or gamma-interferon, EPO, glucagons, calcitonin, heparin, interleukin-1, interleukin-2, filgrastim, a protein, HGH, luteinizing hormone, atrial natriuretic factor, Factoroquinolones, aminoglycosides or macrolides, an
  • diagnostic agent refers to a therapeutic agent which is used as part of a diagnostic test (e.g., a fluorescent dye to be used for viewing the thread in vivo).
  • the diagnostic agent is soluble TB (tuberculosis) protein.
  • lubricity-enhancing agent is intended to refer to a substance or solution which when contacted with the dried thread, acts to lubricate the dried thread.
  • a lubricity- enhancing agent can comprise, for example, water and/or an alcohol, an aqueous buffer, and may further comprise additional agents such as polyethylene glycol, hyaluronic acid, and/or collagen.
  • biodegradation impeding agent is intended to refer to a biocompatible substance that slows or prevents the in vivo degradation of the thread.
  • a biocompatible substance that slows or prevents the in vivo degradation of the thread.
  • biodegradation impeding agent can include hydrophobic agents (e.g., lipids) or sacrificial biodegradation agents (e.g., sugars).
  • hydrophobic agents e.g., lipids
  • sacrificial biodegradation agents e.g., sugars
  • failure stress is intended to refer to the maximum weight which, when applied to the thread, causes the thread to fail. By “failing,” it meant that the thread can break or segment or otherwise lose structural integrity. In some embodiments, the failure stress is about 0.1 pounds or 0.22 kilograms or greater.
  • aqueous gel composition or “gel composition” or “gel mixture” is intended to refer to an aqueous composition comprising water and hyaluronic acid.
  • the composition may further comprise a buffer such that that the pH of the solution changes very little with the addition of components of the composition.
  • the composition is referred to as an aqueous buffered gel composition.
  • the pH of the buffered gel composition is typically from about 7 to about 10. In certain embodiments the pH is about 7. In certain embodiments, the pH is higher at about 9 or about 10. In some embodiments, the pH can be adjusted by adding an appropriate amount of a suitable base, such as Na 2 C0 3 or NaOH.
  • the aqueous gel buffered composition comprises phosphate buffered saline.
  • the aqueous gel buffered composition comprises
  • Tris tris(hydroxymethyl)aminomethane
  • additional solutes are added to adjust the osmolality and ion concentrations, such as sodium chloride, calcium chloride, and/or potassium chloride.
  • Buffer is intended to refer to a solution comprising a mixture of a weak acid and its conjugate base or a weak base and its conjugate acid.
  • Buffer solutions include, but are not limited to, 2-amino-2-methyl-l,3-propanediol, 2-amino-2-methyl-l-propanol, L-(+)-tartaric acid, D-(-)-tartaric acid, ACES, ADA, acetic acid, ammonium acetate, ammonium bicarbonate, ammonium citrate, ammonium formate, ammonium oxalate, ammonium phosphate, ammonium sodium phosphate, ammonium sulfate, ammonium tartrate, BES, BICINE, BIS-TRIS, bicarbonate, boric acid, CAPS, CHES, calcium acetate, calcium carbonate, calcium citrate, citrate, citric acid, diethanolamine, EPP, ethylenediaminetetraacetic acid dis
  • aqueous solvent is intended to refer to a non-toxic, non-immunogenic aqueous composition.
  • the aqueous solvent can be water and/or an alcohol, and may further comprise buffers, salts and other such non-reactive solutes.
  • contact angle or "equilibrium contact angle” refers to a measure of a liquid's affinity for a solid and quantifies the degree of a liquid drop's spread when placed on the solid.
  • the liquid is the aqueous gel composition and the rigid or solid surface is the substrate on which the composition is extruded.
  • the contact angle is a measure of the angle that the edge of an ideal drop makes with a flat surface. The lower that the contact angle is, the greater attraction between the surface and the liquid. For example, water spreads almost completely on glass and has a very low contact angle of nearly 0 degrees. Mercury, in contrast, beads up and spreads very little; its contact angle is very large.
  • the present invention is directed to a thread comprising hyaluronic acid wherein at least a portion of the hyaluronic acid is interlocked.
  • the thread is formed by drying an aqueous gel composition which comprises hyaluronic acid under non-denaturing conditions and preferably ambient conditions so as to provide for the interlocking.
  • intramolecular or intermolecular cross-linking occurs after at least a portion of the polymer chains of the hyaluronic acid in the aqueous gel composition have interlocked.
  • at least a portion of the thread of the invention is intramolecularly and/or intermolecularly cross-linked.
  • intramolecularly or intermolecularly cross-linked is intended to refer intermolecular or intramolecular dehydration which results in lactone or anhydride formation within a single polymer chain or between two or more chains. This is differentiated from two or more polymer chains of hyaluronic acid which have been covalently bonded via a cross-linking agent, such as butanediol diglycidyl ether (BDDE), divinyl sulfone (DVS), and l-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC), or a combination thereof.
  • BDDE butanediol diglycidyl ether
  • DVD divinyl sulfone
  • EDC l-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride
  • the thread is substantially free of cross-linking agents.
  • the portion that is interlocked is the outer surface or the outer surface and the inner surface of the thread. It is further contemplated that the thread is substantially interlocked uniformly along its length. In certain embodiments, it is contemplated that the threads of the invention are not viscoelastic. In one embodiment, the threads of the invention do not have an elasticity along their length of greater than 100%, or greater than 50%>.
  • the interlocking of the hyaluronic acid can be observed by the ability of the thread to reflect polarized light. This can be observed in Fig. 1. As can be seen in the figure, the thread of the invention reflects polarized light but the forms of HA which are not considered interlocked, such as the Restylane® gel, do not reflect polarized light.
  • the interlocking can be quantified by the use of one or more of the following: scanning electron microscopy (SEM), transmission electron microscopy (TEM), atomic force microscopy (AFM) and/or x-ray diffraction (XRD).
  • SEM scanning electron microscopy
  • TEM transmission electron microscopy
  • AFM atomic force microscopy
  • XRD x-ray diffraction
  • the half-life of the hyaluronic acid thread in vivo can be controlled by controlling the thickness of the thread, the density, the molecular weight of the hyaluronic acid and the degree of hydration, which can then be further controlled by adjusting the amounts of hyaluronic acid.
  • the percent hydration of hyaluronic acid can range from about 1%> to greater than about 1000%) based on the total weight.
  • the percent hydration of the thread of the present invention can be controlled, for example, by adjusting the percent hyaluronic acid in the gel. It is contemplated that a lower percent hydration thread would result in a thread with a higher tensile strength.
  • the thread has no more than about 30%> percent, or no more than 15%>, or no more than 10%> by weight hydration based on the total weight. The percent hydration will be determined by the environment to which the thread is subjected to during or after the drying process. [0069] In one embodiment, at least about 10% of the thread is interlocked. In another embodiment, at least about 30% is interlocked. It is further contemplated that a sufficient amount of the thread is interlocked so as to provide the improved mechanical properties of increased strength and/or an enhanced ability to promote fibrogenesis. In one embodiment, the thread is elastomeric. In one embodiment, the thread is not too rigid or too plastic-like so as it can be moved within the dermis during delivery when used as a dermal filler. The appropriate stiffness or elastic modulus is determined by the intended use of the thread.
  • the invention is also directed to a method of making the thread of the invention.
  • the method comprises drying under non-denaturing and preferably ambient conditions an aqueous gel composition comprising hyaluronic acid to provide a dried thread.
  • the aqueous gel composition comprises water and can optionally comprise phosphate buffered saline (PBS) or tris(hydroxymethyl)aminomethane (Tris) buffer and optionally have a pH of about 7.
  • PBS phosphate buffered saline
  • Tris tris(hydroxymethyl)aminomethane
  • the buffer can be selected based on the desired pH of the composition.
  • the pH is adjusted with the appropriate amount of a suitable base, such as Na 2 C0 3 or NaOH to reach the desired pH.
  • the desired amount of HA is added, which is from about 1%) to about 30%) by weight, and is preferably about 5 to about 10%> by weight.
  • the relative amount of HA can be adjusted based on its molecular weight to provide a composition of desired viscosity.
  • the molecular weight of the HA used in the threads of the invention is from about 0.5 MDa to about 3.0 MDa, or from about 1.2 MDa to about 1.8 MDa, or from about 1.4 MDa to about 1.6 MDa.
  • After adding the HA it is allowed to dissolve slowly to form a gel.
  • the viscosity of the gel is typically from about 150 Pascal-seconds (Pa.s) to about 2,000 Pascal-seconds (Pa.s).
  • the gel composition is degassed prior to extrusion to minimize air bubbles after extrusion.
  • the degassing can be done by freeze-pump-thaw which procedure is known by one of skill in the art.
  • the gel composition is typically extruded onto a substrate which is more thoroughly discussed in Example 1 to form a wetted thread.
  • the composition is extruded using a pressurized syringe affixed to a nozzle.
  • the nozzle can have various geometries, such as various lengths, internal diameters and shapes.
  • the nozzle may be circular or non-circular in shape, for example, a flattened shape or a "D" shape.
  • the syringe nozzle may be anywhere from about a 15 gauge to a 25 gauge syringe nozzle.
  • the pressure employed is from about 10 to about 2000 psi or from about 20 to about 240 psi.
  • the pressure requirements are dictated by the nozzle geometry.
  • the pressure can be applied hydraulically, for example using ambient air or nitrogen, or mechanically.
  • the speed at which the gel is extruded is selected so as to minimize air bubbles in the length of the thread and maximize a consistent shape. Air bubbles can reduce the structural integrity of the thread by causing weak spots.
  • Substrates include by hydrophilic and hydrophobic substrates and may be selected from, but are not limited to, polytetrafluoroethylene (PTFE), expanded PTFE, nylon, polyethylene terephthalate (PET), polystyrene, silicon, polyurethane, and activated cellulose.
  • PTFE polytetrafluoroethylene
  • PET polyethylene terephthalate
  • polystyrene silicon
  • polyurethane polyurethane
  • activated cellulose activated cellulose.
  • the substrate employed, along with the viscosity of the gel composition dictates the general shape of the thread. Various shapes are shown in Fig. 11. For example, if the gel and the substrate have an equilibrium contact angle of less than 90 degrees, it is contemplated that the thread formed will be substantially ribbon-shaped (Fig. 11C).
  • the thread formed will be substantially D- shaped (Fig. 1 IB). Still further, if the gel and the substrate have an equilibrium contact angle of greater than 90 degrees, then the thread formed will be substantially round (Fig. 11C). For example, a 10% 1.5 MDa gel will have a substantially round cross-section (e.g., about 80% of a circle) when extruded on PTFE, while a 5% 1.5 MDa gel will form a substantially ribbon-shaped thread when extruded on PTFE. [0077] Alternatively to pressurized extrusion, the gel composition can be rolled out into an elongated cylinder and/or cut into elongated strips before drying.
  • the wetted thread is then dried to form a dried thread.
  • the drying step is required to form threads with a sufficient tensile strength, as discussed below.
  • the drying step be performed under ambient conditions. It is contemplated that by drying under ambient conditions, the hyaluronic acid is allowed to interlock.
  • This drying procedure provides a thread with a higher tensile strength, such as, for example, an ultimate tensile strength of about 8 kpsi or greater or 20 kpsi or greater.
  • the threads of the invention have a failure stress of about 0.1 pounds or 0.22 kilograms or greater.
  • the thread is allowed to dry for anywhere from about 30 minutes to about 72 hours to form threads having a diameter of from 0.05 mm to about 1.0 mm and having no more than 30%> by weight hydration.
  • the thread can be dried for about 12 hours or about 24 hours. It is contemplated that the larger the molecular weight of HA employed or the more concentrated the HA in the composition, the longer the drying times that are required.
  • the threads of the invention can be sterilized using typical sterilization methods known in the art, such as autoclave, ethylene oxide, electron beam (e-beam), supercritical CO 2 (with peroxide), freeze-drying, etc.
  • typical sterilization methods known in the art, such as autoclave, ethylene oxide, electron beam (e-beam), supercritical CO 2 (with peroxide), freeze-drying, etc.
  • the threads of the invention can be sterilized using electron beam (e-beam) sterilization methods.
  • the threads are first washed in a buffer solution at high pH (i.e., pH 9 or pH 10) prior to sterilization.
  • the wash solutions further comprise ethanol, ascorbic acid, vitamin E and/or sodium phosphate.
  • the thread is mechanically stretched prior to drying.
  • the stretching or absence of stretching can provide a thread of the desired length and/or rehydration swelling volume.
  • the length of the thread can be from about 0.5 mm to about 15 mm.
  • the thread Upon drying, the thread, in some embodiments, heals to provide a more uniform surface of the thread. 4. Modification of Threads
  • a therapeutic agent include antibacterials, anesthetics, dyes for viewing placement in vivo, and the like.
  • a dried or hydrated thread is coated to alter the properties with a bioabsorbable biopolymer, such as collagen, PEG, PLGA or a phase transfer PluronicTM which can be introduced as a liquid and which solidifies in vivo.
  • the thread can be coated to modulate the rate at which the thread is rehydrated.
  • the thread can be coated with a hydrophobic layer, such as a lipid. The thickness of the lipid layer can then be adjusted to achieve the desired rate of rehydration.
  • the thread can be coated with an aqueous composition of non-cross-linked hyaluronic acid. This can be performed just prior to implantation of the thread to act as a lubricant. It is also contemplated that this coating with non-cross-linked hyaluronic acid may slow the rate of hydration of the thread.
  • the thread is coated, either totally or in part, with the gel composition to form a layered material. For woven constructs, whether single layer or 3D, can be coated in their entirety to create weaves or meshes with altered physical properties from that of a free-woven mesh.
  • the threads as disclosed herein can be braided, coiled, layered or woven.
  • braids may be formed from the threads described above.
  • a braid can be formed by intertwining three or more threads wherein each thread is functionally equivalent in zigzagging forward through the overlapping mass of the others.
  • the braids can be a flat, three-strand structure, or more complex braids can be constructed from an arbitrary (but usually odd) number of threads to create a wider range of structures, such as wider ribbon-like bands, hollow or solid cylindrical cords, or broad mats which resemble a rudimentary perpendicular weave.
  • a plasticizer is added to adjust the stiffness of the thread.
  • threads of varying stiffness may be weaved together to produce a braided thread or material having the desired stiffness.
  • a three-dimensional structure may be constructed by weaving or wrapping or coiling or layering the threads described above. In other embodiments, a three- dimensional structure may be constructed by weaving or wrapping or coiling or layering the braids described above. In still other embodiments, a three-dimensional structure may be constructed by weaving or wrapping or coiling or layering the cords described above. In still other embodiments, a three-dimensional structure may be constructed by weaving or wrapping or coiling or layering the meshes described above. [0087] In some embodiments, a three-dimensional, cylindrical implant is made of any of the threads is provided. An exemplary use for such an implant is for nipple reconstruction. In some embodiments, the threads used to make the cylindrical implant may include chrondrocyte adhesion compounds. In other embodiments, the cylindrical shape is provided by multiple, concentric coils of threads. 5.
  • the threads, braids, cords, woven meshes or three-dimensional structures described herein can be used, for example, to fill aneurysms, occlude blood flow to tumors, (i.e., tumor occlusion), in eye-lid surgery, in penile augmentation (e.g., for enlargement or for sensitivity reduction, i.e., pre-mature ejaculation treatment), inter-nasal (blood-brain barrier) delivery devices for diagnostic and/or therapeutic agents, corneal implants for drug delivery, nose augmentation or reconstruction, lip augmentation or reconstruction, facial augmentation or reconstruction, ear lobe augmentation or reconstruction, spinal implants (e.g., to support a bulging disc), root canal filler (medicated with therapeutic agent), glottal insufficiency, laser photo-refractive therapy (e.g., hyaluronic acid thread/weave used as a cushion), scaffolding for organ regrowth, spinal cord treatment (BDNF and NGF), in Parkinson
  • Threads of the invention have an improved ability to promote fibrogenesis and/or tissue repair in vivo by forming a scaffold-like structure in the body for collagen deposition. This tissue repair could prolong the "filler" effects of the thread when used to treat or fill a wrinkle in vivo far beyond the half-life of the hyaluronic acid-based thread of the invention. This is described in Example 8.
  • the present invention is directed to a method of treating a wrinkle in a patient in need thereof by 1) inserting the thread of the invention into dermis or subcutaneous space of the patient adjacent to or under the wrinkle; and 2) applying the thread adjacent to or under the wrinkle thereby treating the wrinkle. These steps can be performed at least once and up to 6 times to treat each wrinkle.
  • the thread is attached to the distal end of a syringe as shown in Figs. 3, 4A and 4B. The thread is inserted by a needle which needle is then removed. Optionally and as necessary, the thread is hydrated with water or saline, or by the fluids normally perfusing the surrounding tissue.
  • the remainder of the wrinkle can be filled with a biocompatible material such as a phase transfer PluronicTM which can be introduced as a liquid and which solidifies in vivo.
  • a biocompatible material such as a phase transfer PluronicTM which can be introduced as a liquid and which solidifies in vivo.
  • conventional hyaluronic acid gel can be introduced to fill the wrinkle.
  • the formed web acts to maintain the biocompatible filler at the site of the wrinkle.
  • a method of treating a wrinkle in a subject is provided.
  • the attending clinician may numb the treatment area according to procedures known in the art using a variety of anesthetics, including, but not limited to, topical lidocaine, ice or a block with lidocaine injection.
  • the wrinkle may be in the peri-orbital region as illustrated in Fig.
  • the thread may be attached to a needle as illustrated, for example, in Figs. 3, 4A and 4B.
  • the distal end of the needle may be inserted through the skin surface of the subject into the dermis adjacent to or within the wrinkle as illustrated, for example, in Fig. 5B.
  • the thread is inserted into the subcutaneous space instead of the dermis.
  • the needle then may traverse the dermis or subcutaneous space of the subject beneath the wrinkle as illustrated, for example, in Fig. 5C.
  • the needle then may exit the skin of the subject at the opposite margin of the wrinkle, as illustrated, for example, in Fig. 5D.
  • the needle may then be pulled distally until it is removed from the subject such that the thread is pulled into the location previously occupied by the needle beneath the wrinkle, as illustrated, for example, in Fig. 5E. Finally, excess thread is cut from the needle at the skin surface of the subject which leaves the thread implanted as illustrated, for example, in Fig. 5F.
  • Figs. 7A, 7B and 7C A typical wrinkle is illustrated in Fig. 7A.
  • Fig. 7B illustrates a thread implanted beneath a wrinkle that is not yet hydrated. As the thread implanted beneath the wrinkle becomes fully hydrated the surface appearance of the wrinkle is concurrently flattened as illustrated in Fig. 7C.
  • the thread is manipulated in such a fashion such that one end of the thread is sufficiently hard such that the thread is used to penetrate the skin. This may be accomplished by coating the thread with a hardening material, such as a sugar coating, In another embodiment, the thread is coated in its entirety, for example with a sugar coating, to provide the thread with increased columnar strength.
  • a hardening material such as a sugar coating
  • the above method may be used to rejuvenate the skin of a subject in need thereof.
  • the thread includes substantial amounts of non-cross linked hyaluronic acid.
  • the thread includes
  • antioxidants vitamin E or retinol or combinations thereof.
  • the threads of the invention are useful in facial contouring. What is meant by facial contouring is that the threads can be applied to any area of the face or neck or chest that the patient desires to have augmented, including, by way of example only, the lips, the nasolabial fold (see, Fig. 17A and 17B), tear trough (see, Fig. 16A and 16B), and the forehead (see, Fig. 18A and l 8B).
  • Lip augmentation is a commonly desired aesthetic procedure. Typically, the aesthetic goal is fuller, plumper lips. Available treatment options for lip augmentation include temporary fillers such as Restylane® and Juvederm®, permanent fillers such as ArteFill®, Radiesse® and Goretex® implants, as well as surgical procedures. Areas of enhancement can include the vermillion border (or white roll) for lip effacement and contouring and the wet-dry mucosal junction for increasing fullness. Other techniques include more diffuse infiltration of the orbicularis oris muscle.
  • the present invention addresses the shortcomings described above. Beyond addressing the above-listed shortcomings for existing temporary dermal fillers described above, it has been found that the HA thread-based method of enhancing lip appearance is very quick. A typical patient may have 3 threads placed in their lip(s) in only 3 minutes. Current dermal filler lip procedures can take 15 to 20 minutes. See, Fig. 13A, 13B, 14A, 14B, 15A, and 15B.
  • the attending clinician may numb the treatment area according to procedures known in the art using a variety of anesthetics, including, but not limited to, topical lidocaine, ice or a block with lidocaine injection.
  • Threads made of HA hyaluronic acid
  • the needle can serve as a precise guide, and also be used to predict and correct the implant location prior to pulling the thread into the desired location.
  • This precise delivery mechanism can be used to deliver threads along the vermillion border for contouring, superficially if desired, as well as at the wet-dry junction for plumping, deeper into the lip if desired.
  • threads may be implanted in various tissue planes of the patient to provide a more natural look when performing facial contouring.
  • the threads may be implanted in a manner that forms a hammock in the desired location.
  • the attending clinician may deposit or implant the threads in the epidermis, the dermis, and/or the subcutaneous layer. This technique is referred to as stratifying.
  • Threads can impart different effects on facial features such as wrinkles, contours, folds and troughs depending on where they are implanted.
  • the technique of stratifying the thread implant tissue planes is also successfully used in improving the appearance of nasolabial folds (up to four 0.008" threads), glabellar lines, marionette lines, and lips.
  • This is another technique that is enabled by the HA threads and their implantation method.
  • threads can be implanted in hatch (see, Fig. 19A) and/or cross-hatched patterns (see, Fig. 19B) to effect areas greater than the width of a single thread. As seen in Figs.
  • FIG. 19A and 19B two patients have their tear troughs effectively smoothed out by placing threads parallel in one case (Fig. 19A) and cross-hatched in another case (Fig. 19B).
  • the cross-hatching could be done obliquely to the initial direction, as was the case in Fig. 19B, or perpendicularly.
  • the hatches can be in different tissue planes as well.
  • the hatching can be done obliquely to the directionality of the area being treated.
  • the threads are placed aligned to the axis of the tear trough.
  • the threads could be placed obliquely to the axis of the tear trough to support the tissue in the area differently.
  • implanting the threads in various planes may also be done in the treatment of wrinkles as described above. Wound Therapy
  • the threads, braids, cords, woven meshes or three-dimensional structures described herein are used in wound dressings including negative pressure wound dressings.
  • wound dressing remains in contact with the wound for at least 72 hours.
  • the negative pressure wound dressing remains in contact with the wound for at least 1 week.
  • the wound dressing remains in contact with the wound for at least 2 weeks.
  • the wound dressing remains in contact with the wound for at least 3 weeks.
  • the wound dressing remains in contact with the wound for at least 4 weeks.
  • granulation tissue is not retaining the threads, braids, cords, woven meshes or three- dimensional structures described herein as these components are fully absorbable.
  • the wound dressing is between about 1 cm and about 5 cm thick.
  • wound bed closure may be achieved without changing the dressing.
  • the woven meshes described herein are used in wound dressings including negative pressure wound dressings.
  • the dressing include between 2 and about 10 layers of woven meshes.
  • the woven meshes comprise identical threads. In still other embodiments, the woven meshes comprise different threads.
  • the woven meshes are between about 1 mm and about 2 mm thick when dry. In other embodiments, the woven meshes are between about 2 mm and about 4 mm thick when dry.
  • the pore size of the woven mesh is between about 1 mm and about 10 mm in width. In other embodiments, the pore size of the woven mesh is between about 0.3 mm and about 0.6 mm in width. In still other embodiments, the pores of the woven mesh are aligned. In still other embodiments, the pores of the woven mesh are staggered. In still other embodiments, the woven meshes are collimated to create pores of desired size.
  • the woven mesh is mechanically stable at a minimum vacuum level of about 75 mm Hg. In other embodiments, the woven mesh is mechanically stable at a vacuum up to about 150 mm Hg. [0115] In some embodiments, the woven mesh includes collagen. In other embodiments, the dressing is attached to a polyurethane foam. In still other embodiments, the polyurethane foam is open celled. In still other embodiments, the dressing is attached to a thin film. In still other embodiments, the thin film is silicone or polyurethane. In still other embodiments, the dressing is attached to the thin film with a water soluble adhesive.
  • the thread used in the dressing includes a therapeutic agent or a diagnostic agent.
  • a negative pressure wound dressing (Johnson et al., U.S. Patent No. 7,070,584, Kemp et al., U.S. Patent No. 5,256,418, Chatelier et al., U.S. Patent No. 5,449383, Bennet et al., U.S. Patent No. 5,578,662, Yasukawa et al., U.S. Patent Nos. 5,629,186, 5,780,281 and 7,611,500) is provided for use in vacuum induced healing of wounds, particularly open surface wounds (Zamierski U.S. Patent Nos.
  • the dressing includes a pad which conforms to the wound location, an air-tight seal which is removably adhered to the pad, a negative pressure source in fluid communication with the pad and the threads, braids, cords, woven meshes or three-dimensional structures described herein attached to the wound contacting surface of the pad.
  • the pad, seal and vacuum source are implemented as described in the prior art.
  • the threads, braids, cords, woven meshes or three-dimensional structures described herein are mechanically stable at a minimum vacuum level of about 75 mm Hg. In still other embodiments, the threads, braids, cords, woven meshes or three-dimensional structures described herein are mechanically stable at a vacuum up to about 150 mm Hg. In still other embodiments, the dressing includes at least one layer of woven mesh. In still other embodiments, the dressing include between 2 and about 10 layers of woven mesh. [0119] In some embodiments a tube connects the pad to the negative pressure source. In still other embodiments, a removable canister is inserted between the pad and the negative pressure source and is in fluid communication with both the pad and the negative pressure source.
  • the threads, braids, cords, woven meshes or three-dimensional structures described herein are not hydrated. Accordingly, in these embodiments, the dressing could absorb wound exudates when placed in contact with the wound. In other embodiments, the threads, braids, cords, woven meshes or three-dimensional structures described herein are hydrated. Accordingly, in these embodiments, the dressing could keep the wound moist when placed in contact with the wound.
  • an input port attached to a fluid is connected with the pad.
  • fluid could be dispensed in the wound.
  • the fluid is saline. In other embodiments, the fluid contains diagnostic or therapeutic agents.
  • the threads, braids, cords, woven meshes or three-dimensional structures described herein are used as adhesion barriers. In some embodiments, the woven meshes described herein are used in adhesion barriers. Hair Loss Treatment
  • a method of treating hair loss in a subject is provided.
  • a subject such as, for example, a male with typical male-pattern baldness is illustrated in Fig. 6A and the area where hair growth (with imaginary hairlines) is desired is shown in Fig. 6B.
  • the thread may be attached to a needle as illustrated, for example, in Figs. 3, 4A, 4B and 6C.
  • the distal end of the needle may be inserted into one of the hair lines as illustrated, for example, in Fig. 6C.
  • the needle then may traverse the area beneath the hairline of the subject and then may exit the skin of the subject as illustrated, for example, in Fig. 6D.
  • the needle may then be pulled distally until it is removed from the subject such that the thread is pulled into the location previously occupied by the needle as illustrated, for example, in Fig. 6E. Finally, excess thread is cut from the needle at the skin surface of the subject which leaves the thread implanted as illustrated, for example, in Fig. 6F.
  • the threads, braids, cords, woven meshes or three-dimensional structures described herein are used as dermal fillers in various aesthetic applications as described above. In other embodiments, the threads, braids, cords, woven meshes or three-dimensional structures described herein are used as sutures in various medical and/or surgical applications. In still other embodiments, the threads, braids, cords, woven meshes or three-dimensional structures described herein are used in ophthalmologic surgery, drug delivery and intra-articular injection.
  • a method for treating tumors in a subject in need thereof is provided.
  • the thread may be attached to a needle as illustrated, for example, in Figs. 3, 4A and 4B.
  • the distal end of the needle may be inserted into the tumor of the subject.
  • the needle then may traverse the tumor and then may exit the tumor.
  • the needle may then be pulled distally until it is removed from the tumor of the subject such that the thread is pulled into the location previously occupied by the needle. Finally, excess thread is cut from the needle which leaves the thread implanted in the tumor of the subject.
  • the thread includes an anti-cancer agent.
  • the thread includes Bcl-2 inhibitors.
  • Fig. 8A illustrates a human pancreas with a tumor while Fig. 8B illustrates a needle with a thread attached thereto.
  • the pancreas may be accessed by surgery or minimally invasively methods such as by laparoscopy.
  • the distal end of the needle may be inserted into the pancreatic tumor.
  • the needle then may traverse the pancreatic tumor as illustrated in Fig. 8C and then may exit the tumor.
  • the needle may then be pulled distally until it is removed from the pancreatic tumor such that the thread is pulled into the location previously occupied by the needle.
  • excess thread is cut from the needle which leaves the thread implanted in the pancreatic tumor.
  • the process may be repeated any number of times to provide, as illustrated in Fig. 8D, a pancreatic tumor which has been implanted with a number of threads.
  • the thread includes an anti-cancer agent.
  • a method for treating a varicose vein in subject in need thereof is provided.
  • the thread may be attached to a needle as illustrated, for example, in Figs. 3, 4A and 4B.
  • the distal end of the needle may be inserted into the varicose vein of the subject.
  • the needle then may traverse the varicose vein and then may exit the vein.
  • the needle may then be pulled distally until it is removed from the varicose vein of the subject such that the thread is pulled into the location previously occupied by the needle. Finally, excess thread is cut from the needle which leaves the thread implanted in the varicose vein of the subject.
  • the needle is a flexible.
  • the thread coils when hydrated, more readily occluding the vessel.
  • a method for nipple reconstruction where a three- dimensional, cylindrical implant comprised of threads is implanted underneath the skin.
  • the implant may include therapeutic agents, for example chrondrocyte adhesion compounds.
  • Fig. 9A illustrates an implant of multiple layers of concentric coils of threads shaped to represent a nipple while Fig. 9B shows a cross-section of the implant of Fig. 9A.
  • Fig. 9C illustrates how the implant of Fig. 9A could be used for nipple reconstruction.
  • methods for nerve or vessel regrowth are provided. As illustrated in Fig. 10, a needle can be used to place a thread in a specific line which could promote nerve or vessel regeneration.
  • kits [0130] Also proved herein is a kit of parts comprising a thread of the invention.
  • the kit comprises a thread and a means for delivering or implanting the thread to a patient.
  • the means for delivery to a patient is a syringe or a needle.
  • the means for delivery to a patient is an air gun.
  • the size (or diameter) of the needle may depend on the use of the thread, and therefore also be based on the cross-sectional area of the thread used.
  • the outer diameter of the needle or syringe may be greater than or equal to the cross-sectional area of the thread used to lessen the tensile requirement of the thread as it is being applied to the dermis.
  • the outer diameter of the thread may be larger than the outer diameter of the needle. Skin is quite pliable so by having a smaller diameter needle can allow the puncture size to be small even with the use of a larger diameter thread. Further, the thickness of the thread would be different in the case where the thread is a suture in comparison to the treatment of fine lines and wrinkles where it may be that a thinner thread is used. More than one thread may also be attached to a single needle.
  • the size of the delivery device a needle
  • the size of the delivery device will be dependent on its intended use and the size of the thread. It is contemplated that for use in facial contouring and or wrinkle filling a 0.006 to about 0.008" diameter thread or a 0.003 to about 0.004" diameter thread will be sufficient.
  • the needle is stainless steel. In other embodiments, the size of the thread is from about 0.01" to 0.02" in diameter.
  • the thread attachment to the needle can be either a mechanical attachment and/or with the use of an adhesive, such as cyanoacrylate.
  • an adhesive such as cyanoacrylate.
  • the thread can be made to form a physical attachment to the needle during the drying process as the thread forms from the gel.
  • the pores can fill with the gel during the extrusion process and the thread would be thus be secured upon drying.
  • the needle can be rigid or flexible to enable the user to track the needle under the wrinkle within the dermis.
  • the needle may be equipped with a ramp to guide the needle at a desired depth within the dermis, and after needle insertion, the guide may be unclasped as the needle is brought through the skin surface.
  • the thread is attached to a needle.
  • the kit comprises a needle and the thread attached thereto, is packaged sterile, and intended for single use.
  • a kit can comprise several needles, each with an attached thread.
  • a kit includes threads of different sizes to enable treatment options for the physician while minimizing the number of required needle sticks.
  • the kit includes threads and needles of different length and curved shapes to simplify implantation in areas that are difficult to access or treat with a straight needle, for example near the nose, around the eyes and the middle portion of the upper lip.
  • a hyaluronic acid thread of a diameter of up to 1 mm can be made by the following procedure. It is contemplated that a thread as prepared below can be stored under ambient conditions for greater than 9 months without a loss of its structural integrity or interlocking.
  • the desired amount of hyaluronic acid is weighed out into a suitable container and an aqueous solution, such as deionized water, is added to result in the desired % HA gel by weight.
  • the HA is allowed to slowly dissolve in the aqueous solution at a temperature of about 4-10 °C for 8 to 24 hours until the HA has completely swelled thus forming a gel.
  • hyaluronic acid e.g. >2MDa
  • % gels e.g. >10%
  • the viscosity of the gel composition is from about 150 Pascal- seconds (Pa.s) to about 2,000 Pascal-seconds (Pa.s).
  • the gel can be degassed by applying a vacuum or by freeze -pump-thaw cycles either prior to or after the addition of the cross-linking agent.
  • the gel composition is then transferred to a pressurized extruder (e.g., EFD Model XL 1500 pneumatic dispense machine).
  • a pressurized extruder e.g., EFD Model XL 1500 pneumatic dispense machine.
  • the nozzle of the extruder can have a tip ranging from a 15 gauge to about 25 gauge.
  • the syringe pressure may be between about 10 psi and about 2,000 psi, depending on the viscosity of the gel composition. For very viscous gels, a pressure multiplier can be used.
  • the wetted thread is then be formed by extruding the gel composition onto a substrate by an extruder which is linearly translating at a speed commensurate with the speed of gel ejection from the syringe to achieve the desired wetted thread thickness.
  • the wetted thread is then dried under ambient conditions for about 12 hours to a percent hydration of less than about 30%, or less than about 15%, or less than about 10%, thus providing a dried thread.
  • the thread can be allowed to dry under a relative humidity of from about 20% to about 80%> at a temperature of from about 20 °C to about 37 °C.
  • the wetted thread can be stretched to a desired length and reduced diameter prior to dying.
  • the stretching can be by either hanging the thread by one end and applying weight to the opposing end, or by horizontally stretching the wetted thread on a surface (either the same or different from the extrusion surface) and adhering the ends to the surface.
  • Example 2 Threads vs Restylane® Threads
  • Restylane® was used as a gel composition in an attempt to form threads using the methods provided herein. Although a thread was produced, the thread did not show similar mechanical properties to the treads formed by the methods disclosed herein. A 0.007 inch x 0.020 inch Restylane® thread failed at 0.08 kg, which is far weaker than the threads of the present invention.
  • Example 5 Treatment of Wrinkles of a Cadaver with Hyaluronic Acid Threads
  • Hypodermic needles (22 to 25 Ga) were affixed with single or double strands of hyaluronic acid threads ranging from thicknesses of 0.004 in to 0.008 in with LocTite® 4014.
  • the needles were able to traverse wrinkles in a cadaveric head of a 50 year old woman such as the naso-labial fold, peri-orals, peri-orbitals, frontalis (forehead), and glabellar.
  • the needle was able to pull the thread through the skin such that the thread was located where the needle was previously inserted. More than one thread was used to treat the wrinkles in order to achieve the desired fill effect (two to four threads). Since cadaveric tissue does not have the same hydration characteristics as living tissue, the threads were then hydrated by applying a 0.9% saline solution to the treated area. The wrinkle was visibly lessened upon thread hydration.
  • hypodermic needles 22 to 25 Ga
  • hyaluronic acid threads ranging from thicknesses of 0.004 in to 0.008 in with LocTite® 4014.
  • the samples were e-beam sterilized by NuTek Corp. at 29 kGy. In all cases, the needle was able to pull the attached thread or threads into the dermis. Within minutes most threads produced a visible impact on the skin surface of the animals in the form of a linear bump.
  • Example 7 Organization and Interlocking of the Threads via Scanning Electron
  • SEM Scenor Microscopy
  • a 10% 1.5 MDa HA thread was prepared as described in Example 1 and was compared to a 10%) 1.5 MDa HA gel using scanning electron microscopy (SEM) (Fig. 2).
  • SEM Scenor
  • the SEM (Scanning Electron Microscope) analysis was performed on the FEI Quanta 600 SEM.
  • the thread was mounted on a double-sided carbon tape and coated with a thin layer of iridium (Ir) to avoid charging.
  • Ir iridium
  • a small portion of the HA gel was transferred to a piece of the clean silicon wafer.
  • the gel (Fig. 2A) and the thread (Figs. 2B, 2C and 2D) have very different surface morphology. SEM images were acquired at multiple locations to ensure the morphology differences observed are representative sample differences.
  • Example 8 In Vitro or In Vivo Testing Regarding Increase in Fibrogenesis
  • the in vivo stimulation of collagen production caused by the threads of the invention can be accomplished using methods known in the art. For example, according to the methods of Wang et al. (Arch Dermatol. (2007) 143(2):155-163), the thread can be applied to a patient followed by a biopsy of the treatment area at one or more time intervals following treatment. The de novo synthesis of collagen can then be assessed using immunohistochemical analysis, quantitative polymerase chain reaction, and electron microscopy.
  • the threads as disclosed herein will result in the synthesis of collagen at the treatment site, thus prolonging the wrinkle filling effects of the threads beyond the half-life the thread (Fig. 15 A and 15B) .
  • Hyaluronic acid is a water binding polymer that present in the mammalian tissues.
  • the swelling and water intake within HA aggregates depend on propensity of water molecules to interact with the polar groups of this polymer.
  • IR spectroscopy studies on HA films in the dried and hydrated states have demonstrated that the presence of intramolecular hydrogen-bonded organization in the dried state (Haxaire et al. (2003) Biopolymers, 72(3): 149-161). Upon interaction with water, this organization develops into hydrogen-bonded intermolecular structures where nano aggregates of water bridge the HA molecules.
  • Threads made by the methods above were tested for the percent hydration via Karl Fisher titration.
  • the threads were prepared with 1.5 MDa HA according to the methods of Example 1.
  • the thread showed organization and interlocking of the hyaluronic acid helices. This can be seen in Figs. 12C and 12D.
  • the hyaluronic acid helices are the dark horizontal bands observed in the direction of the thread axis. Interlocking of the helices can be observed, for example, in Fig. 12D as vertical helices can be seen in the image.
  • Example 11 Lip Augmentation
  • a patient was implanted with HA threads for lip enhancement, for contouring and plumping.
  • the patient received only topical anesthetic on the face, but it was not applied specifically to the lips. The following procedure was followed:
  • sterile primarily water solutions such as phosphate-buffered saline, or injection grade water can be applied directly or applied on a damp cloth to cause the excess thread to revert to a gel and the thread will separate from the needle.
  • each area is treated with 1 to 2 threads wherein each thread has a diameter of anywhere from 200 microns to about 500 microns when the thread is dry. After hydration, it is contemplated that the thread has a diameter of from 0.5 millimeters to about 5 millimeters.

Abstract

La présente invention concerne de façon générale des fils d'acide hyaluronique, des méthodes de fabrication de tels fils et leurs applications, par exemple dans des applications esthétiques (par exemple le tracé des contours faciaux ou le comblement des pores cutanés), en chirurgie (par exemple les sutures), en libération de médicaments, en traitement des plaies par pression négative, en bandage des plaies humides, etc.
PCT/US2011/022640 2010-03-01 2011-01-26 Fils d'acide hyaluronique et leurs méthodes d'utilisation WO2011109130A1 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US30935310P 2010-03-01 2010-03-01
US61/309,353 2010-03-01
US34732510P 2010-05-21 2010-05-21
US61/347,325 2010-05-21
US40517110P 2010-10-20 2010-10-20
US61/405,171 2010-10-20

Publications (1)

Publication Number Publication Date
WO2011109130A1 true WO2011109130A1 (fr) 2011-09-09

Family

ID=44542494

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/022640 WO2011109130A1 (fr) 2010-03-01 2011-01-26 Fils d'acide hyaluronique et leurs méthodes d'utilisation

Country Status (1)

Country Link
WO (1) WO2011109130A1 (fr)

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015112912A1 (fr) 2014-01-27 2015-07-30 Allergan Holdings France S.A.S. Dispositif d'administration de substance
US9228027B2 (en) 2008-09-02 2016-01-05 Allergan Holdings France S.A.S. Threads of Hyaluronic acid and/or derivatives thereof, methods of making thereof and uses thereof
US20160009828A1 (en) * 2013-03-20 2016-01-14 Ildong Pharm Co., Ltd. Preparation method for hyaluronic acid, and anti-adhesive composition comprising hyaluronic acid prepared by same preparation method
CN108463242A (zh) * 2016-03-02 2018-08-28 梅尔兹制药公司 包含肉毒杆菌毒素的组合物
US10258447B2 (en) 2017-01-24 2019-04-16 Allergan Industrie Sas Thread insertion devices
US10265151B2 (en) 2017-01-24 2019-04-23 Allergan Industrie Sas Thread insertion devices
US10363029B2 (en) 2011-06-17 2019-07-30 Allergan Holdings France S.A.S. Needle for delivery of dermal filler threads
US10433928B2 (en) 2015-03-10 2019-10-08 Allergan Pharmaceuticals Holdings (Ireland) Unlimited Company Multiple needle injector
USD865948S1 (en) 2017-03-24 2019-11-05 Allergan, Inc. Syringe device
EP3581117A1 (fr) 2013-03-12 2019-12-18 Allergan Holdings France S.A.S. Aiguille émoussée pour l'administration de fils de remplissage dermique
US10595977B2 (en) 2017-01-24 2020-03-24 Allergan Industrie, Sas Thread insertion devices
US10596321B2 (en) 2016-04-08 2020-03-24 Allergan, Inc. Aspiration and injection device
US10709444B2 (en) 2017-01-24 2020-07-14 Allergan Industrie Sas Thread insertion devices
US10792427B2 (en) 2014-05-13 2020-10-06 Allergan, Inc. High force injection devices
US10820900B2 (en) 2017-01-24 2020-11-03 Allergan Industrie Sas Thread insertion devices
US11155802B2 (en) 2017-07-06 2021-10-26 Merz Pharma Gmbh & Co. Kgaa Recombinant botulinum neurotoxins with increased duration of effect
US11185641B2 (en) 2014-10-01 2021-11-30 Allergan, Inc. Devices for injection and dosing
US11684719B2 (en) 2013-05-23 2023-06-27 Allergan, Inc. Methods of treatment using a syringe extrusion accessory
US11952601B2 (en) 2017-06-20 2024-04-09 Merz Pharma Gmbh & Co. Kgaa Recombinant botulinum toxin with increased duration of effect
US11969461B2 (en) 2016-03-02 2024-04-30 Merz Pharma Gmbh & Co. Kgaa Composition comprising botulinum toxin

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5644049A (en) * 1992-07-03 1997-07-01 M.U.R.S.T. Italian Ministry For Universitites And Scientific And Technology Research Biomaterial comprising hyaluronic acid and derivatives thereof in interpenetrating polymer networks (IPN)
US5718012A (en) * 1996-05-28 1998-02-17 Organogenesis, Inc. Method of strength enhancement of collagen constructs
US20020026039A1 (en) * 1996-08-29 2002-02-28 Davide Bellini Hyaluronic acid esters, threads and biomaterials containing them, and their use in surgery
US20060040894A1 (en) * 2004-08-13 2006-02-23 Angiotech International Ag Compositions and methods using hyaluronic acid
US20080207560A1 (en) * 2005-01-07 2008-08-28 Ayako Harada Composition For External Use

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5644049A (en) * 1992-07-03 1997-07-01 M.U.R.S.T. Italian Ministry For Universitites And Scientific And Technology Research Biomaterial comprising hyaluronic acid and derivatives thereof in interpenetrating polymer networks (IPN)
US5718012A (en) * 1996-05-28 1998-02-17 Organogenesis, Inc. Method of strength enhancement of collagen constructs
US20020026039A1 (en) * 1996-08-29 2002-02-28 Davide Bellini Hyaluronic acid esters, threads and biomaterials containing them, and their use in surgery
US20060040894A1 (en) * 2004-08-13 2006-02-23 Angiotech International Ag Compositions and methods using hyaluronic acid
US20080207560A1 (en) * 2005-01-07 2008-08-28 Ayako Harada Composition For External Use

Cited By (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9228027B2 (en) 2008-09-02 2016-01-05 Allergan Holdings France S.A.S. Threads of Hyaluronic acid and/or derivatives thereof, methods of making thereof and uses thereof
US9861570B2 (en) 2008-09-02 2018-01-09 Allergan Holdings France S.A.S. Threads of hyaluronic acid and/or derivatives thereof, methods of making thereof and uses thereof
US11154484B2 (en) 2008-09-02 2021-10-26 Allergan Holdings France S.A.S. Threads of hyaluronic acid and/or derivatives thereof, methods of making thereof and uses thereof
US10363029B2 (en) 2011-06-17 2019-07-30 Allergan Holdings France S.A.S. Needle for delivery of dermal filler threads
EP3581117A1 (fr) 2013-03-12 2019-12-18 Allergan Holdings France S.A.S. Aiguille émoussée pour l'administration de fils de remplissage dermique
US20160009828A1 (en) * 2013-03-20 2016-01-14 Ildong Pharm Co., Ltd. Preparation method for hyaluronic acid, and anti-adhesive composition comprising hyaluronic acid prepared by same preparation method
CN105324486A (zh) * 2013-03-20 2016-02-10 日东制药株式会社 透明质酸的制造方法和含有通过上述制造方法制造的透明质酸的防粘连用组合物
CN105324486B (zh) * 2013-03-20 2020-09-01 日东制药株式会社 透明质酸的制造方法和含有通过上述制造方法制造的透明质酸的防粘连用组合物
US11684719B2 (en) 2013-05-23 2023-06-27 Allergan, Inc. Methods of treatment using a syringe extrusion accessory
WO2015112912A1 (fr) 2014-01-27 2015-07-30 Allergan Holdings France S.A.S. Dispositif d'administration de substance
US10661022B2 (en) 2014-01-27 2020-05-26 Allergan, Inc. Substance delivery device
US9968745B2 (en) 2014-01-27 2018-05-15 Allergan Holdings France S.A.S. Substance delivery device
US10792427B2 (en) 2014-05-13 2020-10-06 Allergan, Inc. High force injection devices
US11185641B2 (en) 2014-10-01 2021-11-30 Allergan, Inc. Devices for injection and dosing
US10433928B2 (en) 2015-03-10 2019-10-08 Allergan Pharmaceuticals Holdings (Ireland) Unlimited Company Multiple needle injector
US11969461B2 (en) 2016-03-02 2024-04-30 Merz Pharma Gmbh & Co. Kgaa Composition comprising botulinum toxin
CN108463242A (zh) * 2016-03-02 2018-08-28 梅尔兹制药公司 包含肉毒杆菌毒素的组合物
US11890457B2 (en) 2016-04-08 2024-02-06 Allergan, Inc. Aspiration and injection device
US10596321B2 (en) 2016-04-08 2020-03-24 Allergan, Inc. Aspiration and injection device
US10265151B2 (en) 2017-01-24 2019-04-23 Allergan Industrie Sas Thread insertion devices
US11224501B2 (en) 2017-01-24 2022-01-18 Allergan Industrie, Sas Thread insertion devices
US10595977B2 (en) 2017-01-24 2020-03-24 Allergan Industrie, Sas Thread insertion devices
US10258447B2 (en) 2017-01-24 2019-04-16 Allergan Industrie Sas Thread insertion devices
US10820900B2 (en) 2017-01-24 2020-11-03 Allergan Industrie Sas Thread insertion devices
US11039910B2 (en) 2017-01-24 2021-06-22 Allergan Industrie Sas Thread insertion devices
US11883017B2 (en) 2017-01-24 2024-01-30 Allergan Industrie Sas Thread insertion devices
US10709444B2 (en) 2017-01-24 2020-07-14 Allergan Industrie Sas Thread insertion devices
USD865949S1 (en) 2017-03-24 2019-11-05 Allergan, Inc. Syringe device
USD865950S1 (en) 2017-03-24 2019-11-05 Allergan, Inc. Syringe device
USD866753S1 (en) 2017-03-24 2019-11-12 Allergan, Inc. Syringe device
USD865948S1 (en) 2017-03-24 2019-11-05 Allergan, Inc. Syringe device
USD867582S1 (en) 2017-03-24 2019-11-19 Allergan, Inc. Syringe device
US11952601B2 (en) 2017-06-20 2024-04-09 Merz Pharma Gmbh & Co. Kgaa Recombinant botulinum toxin with increased duration of effect
US11155802B2 (en) 2017-07-06 2021-10-26 Merz Pharma Gmbh & Co. Kgaa Recombinant botulinum neurotoxins with increased duration of effect

Similar Documents

Publication Publication Date Title
US20160213813A1 (en) Threads of cross-linked hyaluronic acid and methods of uses thereof
WO2011109130A1 (fr) Fils d'acide hyaluronique et leurs méthodes d'utilisation
US20150327972A1 (en) Soft tissue augmentation threads and methods of use thereof
EP2629809B1 (fr) Fils d'acide hyaluronique reticule, procedé de preparation et utilisation
DK2766056T3 (en) THREAD OF THE CROSS-LOWER HYALURONIC ACID AND PROCEDURES FOR USING IT
US11154484B2 (en) Threads of hyaluronic acid and/or derivatives thereof, methods of making thereof and uses thereof
AU2015201245B2 (en) Threads of hyaluronic acid and/or derivatives thereof, methods of making thereof and uses thereof
NZ623909B2 (en) Threads of cross-linked hyaluronic acid and methods of use thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11751039

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11751039

Country of ref document: EP

Kind code of ref document: A1